Qianhong Pharmaceutical said at the performance briefing on October 26 that the company's QhrD106 injection program is currently in the phase IIb clinical completion stage. After completing communication with the national CDE, it will promptly advance phase III clinical and marketing application related work.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.